Free Trial
NASDAQ:SNDX

Syndax Pharmaceuticals (SNDX) Stock Price, News & Analysis

Syndax Pharmaceuticals logo
$18.86
-0.06 (-0.32%)
(As of 10/31/2024 ET)

About Syndax Pharmaceuticals Stock (NASDAQ:SNDX)

Key Stats

Today's Range
$18.67
$19.25
50-Day Range
$17.93
$20.93
52-Week Range
$12.95
$25.34
Volume
680,644 shs
Average Volume
1.05 million shs
Market Capitalization
$1.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.90
Consensus Rating
Moderate Buy

Company Overview

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Syndax Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
81st Percentile Overall Score

SNDX MarketRank™: 

Syndax Pharmaceuticals scored higher than 81% of companies evaluated by MarketBeat, and ranked 254th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Syndax Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Syndax Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Syndax Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Syndax Pharmaceuticals are expected to grow in the coming year, from ($3.66) to ($3.37) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Syndax Pharmaceuticals is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Syndax Pharmaceuticals is -5.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Syndax Pharmaceuticals has a P/B Ratio of 2.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Syndax Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    12.37% of the outstanding shares of Syndax Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Syndax Pharmaceuticals has recently increased by 4.27%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Syndax Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Syndax Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.37% of the outstanding shares of Syndax Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Syndax Pharmaceuticals has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Syndax Pharmaceuticals has recently increased by 4.27%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Syndax Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Syndax Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 2 people have searched for SNDX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Syndax Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days.
Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNDX Stock News Headlines

Syndax Pharmaceuticals (NASDAQ:SNDX) Now Covered by UBS Group
Watch this before it gets removed
If you missed it, my emergency election broadcast is now available - but will be removed soon
Syndax initiated with a Buy at UBS
See More Headlines

SNDX Stock Analysis - Frequently Asked Questions

Syndax Pharmaceuticals' stock was trading at $21.61 at the beginning of 2024. Since then, SNDX shares have decreased by 12.7% and is now trading at $18.86.
View the best growth stocks for 2024 here
.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released its earnings results on Thursday, August, 1st. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.11. The firm's revenue for the quarter was up 3499999990.0% on a year-over-year basis.

Syndax Pharmaceuticals (SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Top institutional investors of Syndax Pharmaceuticals include Assenagon Asset Management S.A. (0.55%), Inspire Investing LLC (0.03%), Creative Planning (0.02%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Dennis Podlesak, William Meury, Keith Katkin, Pierre Legault, Briggs Morrison, Michael A Metzger, Alexander Nolte, Peter Ordentlich and Fabrice Egros.
View institutional ownership trends
.

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Syndax Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and ServiceNow (NOW).

Company Calendar

Last Earnings
8/01/2024
Today
10/31/2024
Next Earnings (Confirmed)
11/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SNDX
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.90
High Stock Price Target
$45.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+87.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-209,360,000.00
Pretax Margin
-7,545.20%

Debt

Sales & Book Value

Annual Sales
$3.50 million
Book Value
$6.53 per share

Miscellaneous

Free Float
81,607,000
Market Cap
$1.62 billion
Optionable
Optionable
Beta
0.91

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:SNDX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners